Mean height‐for‐age z‐score · children under 5 years old
Nutrition systems strengthening interventions targeting children may leads to higher height‐for‐age (z‐score) at 18 months compared with no intervention or standard care to reduce stunting (height‐for‐age,… (low certainty).
1 finding from 1 review
Stunting · children under 5 years old
1 finding from 1 review
Stunting · children under 5 years old
Micronutrient or macronutrient supplementation interventions in… showed no clear difference in height‐for‐age (z‐score) compared with no intervention, or placebo to reduce stunting (height‐for‐age,… (low certainty).
1 finding from 1 review
Height‐for‐age (z‐score) Length gain (6 months) · children under 5 years old
1 finding from 1 review
Height‐for‐age (%) at 18 months, 21 months Length gain · children under 5 years old
1 finding from 1 review
Resource implications (e.g. cost of incontinence management methods) · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 14 years with overactive bladder and at least one episode of daytime urinary incontinence per week
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 15 years with dysfunctional elimination syndrome, 41/59 with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 3 to 18 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5‐14 years with daytime urinary incontinence or post‐micturition dribbling
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 4 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 6 to 12 years with overactive bladder with urge incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prostatitis symptoms Subgroup: Intraprostatic injection, participants age > 50 years old, basal NIH‐CPSI score > 30 · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Prostatitis symptoms Subgroup: Pelvic floor muscles injection, participants age < 50 years old, basal NIH‐CPSI score < 30 · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Body image · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
CBA: Average lost work time per 100 person‐years · workers
2 findings from 1 review
Cumulative cases of typhoid fever at 2 years · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to lower cumulative cases of typhoid fever at 2 years compared with control (moderate certainty).
2 findings from 1 review
Cumulative cases of typhoid fever at 2.5 to 3 years · adults and children aged 5 years of age and older
Ty21a vaccine (three doses) probably leads to lower cumulative cases of typhoid fever at 2.5 to 3 years compared with control (moderate certainty).
1 finding from 1 review